Protagonist Therapeutics — Third Quarter 2026 Earnings Summary

Protagonist Therapeutics reported a net income of $220.0 million for the third quarter of 2026, driven primarily by $275 million in payments triggered by the FDA approval of MIMRYLO for polycythemia vera. The company's cash, cash equivalents, and marketable securities increased to $834.6 million as of September 30, 2026, following the receipt of these milestone and opt-out payments from partner Takeda. Additionally, Protagonist announced a $300 million share repurchase program and plans to initiate a Phase 2b study for its oral IL-17 antagonist, PN-881, in early 2027. The company also secured regulatory approvals for its oral IL-23 antagonist, ICOTYDE, in China, Japan, and the European Union during the quarter.